Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  aldesleukin
Find trials that include:  Any drugs shown
Results 1-25 of 47 for your search:
Start Over
Genetically Modified T Cells in Treating Patients with Malignant Gliomas
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 11-C-0266, NCI-2013-01508, 110266, 1103-1095, P11810, RD-11-III-06, NCT01454596
Hydroxychloroquine and Aldesleukin in Treating Patients With Metastatic Kidney Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IIT11PLK01, NCI-2012-00427, 11-080, 1302010628, NCT01550367
Genetically Engineered Lymphocytes in Treating Patients with Metastatic Cancer or Cancer That Cannot Be Removed by Surgery Receiving Chemotherapy and Aldesleukin
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 66
Trial IDs: 12-C-0111, NCI-2013-01516, 1112-1139, 120111, P11928, RD-12-I-02, NCT01583686
Laboratory-Treated T Cells in Treating Patients with High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated with Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 2498.00, NCI-2011-03362, 2498, NCT01640301
Umbilical Cord Blood-Derived Natural Killer Cells, Lenalidomide, High-Dose Melphalan, and Stem Cell Transplant in Treating Patients with Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 75
Trial IDs: 2011-0379, NCI-2014-01096, NCI-2014-00541, RV-MM-PI-0691, NCT01729091
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients with Stage III or Metastatic Melanoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 14 and over
Trial IDs: 2009-0471, NCI-2014-02655, NCT01740557
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients with High Risk Myeloid Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 65 and under
Trial IDs: 2012-0819, NCI-2013-00993, RP110553-P3), NCT01823198
Gene Therapy in Treating Patients with Metastatic or Locally Advanced Cancer That Is Recurrent or Refractory
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 66
Trial IDs: 14-C-0052, NCI-2014-02650, 1310-1253, 140052, P131408, RD-13-X-03, NCT02111850
Genetically Engineered Lymphocytes and Aldesleukin after Cyclophosphamide and Fludarabine Phosphate in Treating Patients with Metastatic or Locally Advanced Refractory/Recurrent Cancer That Expresses MAGE-A3
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 66
Trial IDs: 14-C-0110, NCI-2014-02496, 140110, 1402-1293, 338101, P131467, RD-14-III-03, NCT02153905
OKT3/Humanized 3F8 Bispecific Antibody-Activated T Lymphocytes, Aldesleukin, and Sargramostim in Treating Younger Patients with GD2-Positive Metastatic, Recurrent or Refractory Solid Tumors
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 months to 29 years
Trial IDs: 2013-171, NCI-2014-01149, 1403012875, NCT02173093
Genetically Modified Lymphocytes in Treating Patients with Thyroglobulin-Expressing Thyroid Cancer That Is Recurrent or Metastatic and Cannot Be Removed by Surgery
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 66
Trial IDs: 15-C-0090, NCI-2015-00499, 1412-1366, 150090, 342570, 8340274, P141702, RD14-XII-05, NCT02390739
Genetically Modified T Cells in Treating Patients with Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2727.00, NCI-2015-00329, 2727, NCT02408016
Bispecific Antibody Armed Activated T-cells with Aldesleukin and Sargramostim in Treating Patients with Locally Advanced or Metastatic Pancreatic Cancer
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2015-100, NCI-2015-01942, 1510014428, NCT02620865
Gene Therapy and Vaccine Therapy after a Conditioning Regimen in Treating Patients with Stage IIIC-IV Melanoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 08-02-020, NCI-2010-00229, 0802-901, 10-001212, 1600, 53.08.0-h, 53.0B.0·h, MART-1 F5 TCR, OB02·901, NCT00910650
Tumor Infiltrating Lymphocytes and Aldesleukin after Chemotherapy and Pembrolizumab in Treating Patients with Metastatic Cancers
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-C-0166, NCI-2013-01461, 100166, 306343, P09567, NCT01174121
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer and High Dose Aldesleukin in Treating Patients With Metastatic Melanoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC #16992, NCI-2012-01379, NCT01659151
Gene and Vaccine Therapy in Treating Patients with Advanced Malignancies
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 16 and over
Trial IDs: 12-000153, NCI-2012-01548, NCT01697527
Risk-Directed Therapy in Treating Young Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: ALLR18, NCI-2012-00587, NCT01700946
Tumor-Infiltrating Lymphocytes after Combination Chemotherapy in Treating Patients with Metastatic Melanoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2643.00, NCI-2013-00486, NCT01807182
Combination Chemotherapy and Tumor Infiltrating Lymphocytes with or without High Dose Aldesleukin in Treating Patients with Metastatic Ocular Melanoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 70
Trial IDs: 13-C-0093, NCI-2013-01586, 130093, P131209, NCT01814046
High-Dose Aldesleukin and Stereotactic Body Radiation Therapy in Treating Patients with Metastatic Kidney Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: STU 012013-041, NCI-2015-01670, NCT01896271
Laboratory Treated T-Cells in Treating Patients with NY-ESO-1 Expressing Metastatic or Locally Advanced Recurrent Solid Tumors or Malignant Meningioma
Status: Temporarily closed
Phase: Phase II
Type: Treatment
Age: 18 to 66
Trial IDs: 13-C-0214, NCI-2015-00137, 130214, 1308-1249, P131300, RD-13-VII-07, NCT01967823
Tumor Infiltrating Lymphocytes, Aldesleukin, Chemotherapy, and Pembrolizumab in Treating Patients with Metastatic Melanoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 66
Trial IDs: 14-C-0022, NCI-2014-02337, P131421, NCT01993719
CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients with Metastatic Melanoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2012-1055, NCI-2014-01040, NCT02027935
Start Over